Definium Therapeutics presents positive Phase 3 DT120 ODT data in generalized anxiety disorder and major depressive disorder at the 2026 NEI Fall Congress

Definium Therapeutics announced four poster presentations at the 2026 NEI Fall Congress covering its DT120 orally disintegrating tablet program in generalized anxiety disorder and major depressive disorder. The presentations include positive topline results from Panorama, the second Phase 3 GAD study, along with encore presentations of Emerge data in MDD and Voyage data in GAD, plus a combined Phase 3 safety overview. Panorama enrolled 245 adults and evaluated single 50 or 100 microgram doses versus placebo over a 12-week double-blind period followed by a 40-week extension. Voyage enrolled 214 adults with GAD, while Emerge enrolled 149 participants with MDD. DT120 is Definium's proprietary formulation of lysergide, or LSD, a serotonergic psychedelic acting partly through 5-HT2A receptors. The announcement describes the results as positive but does not provide numerical efficacy or safety outcomes.